Non-nucleoside reverse transcriptase inhibitors (Formulary)

EFAVIRENZ

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 600mg (hospital use only)

Important: Formulation and dosage details

Formulation:

Capsules 50mg, 100mg, 200mg (hospital use only)

ETRAVIRINE

Important: Therapy notes

  • MHRA advice: Etravirine: reports of severe hypersensitivity reactions (December 2014)

Important: Formulation and dosage details

Formulation:

Tablets 100mg (hospital use only)

NEVIRAPINE

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 200mg (hospital use only)

Important: Formulation and dosage details

Formulation:

Modified release tablets 400mg (hospital use only)

RILPIVIRINE

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablet 25mg (hospital use only)

Editorial Information

Document Id: F281